{"ticker": {"uuid": "658b160b-fa3e-4570-85a8-979b90392852", "symbol": "CTNM", "name": "Contineum Therapeutics, Inc. Class A Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Contineum Therapeutics CSO Lorrain Daniel S. sells $16,640 in stock", "summary": "Contineum Therapeutics' Chief Scientific Officer, Daniel S. Lorrain, sold 1,040 shares of the company's Class A Common Stock for a total of $16,640 on July 8 and 9, 2026. These sales followed an exercise of stock options at a price of $1.01 per share and were conducted under a 10", "url": "https://www.investing.com/news/insider-trading-news/contineum-therapeutics-cso-lorrain-daniel-s-sells-16640-in-stock-93CH-4787023", "source_name": "Investing.com", "published_at": "2026-07-11T14:41:12", "published_display": "11 Jul 2026 14:41", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics (NASDAQ: CTNM) CSO sells 1,040 shares, exercises options", "summary": "Contineum Therapeutics' Chief Scientific Officer, Daniel S. Lorrain, exercised options for 1,040 shares at $1.01 each and subsequently sold those shares at $16.00 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted in September 202", "url": "https://www.stocktitan.net/sec-filings/CTNM/form-4-contineum-therapeutics-inc-insider-trading-activity-58d2336ab72b.html", "source_name": "Stock Titan", "published_at": "2026-07-10T21:40:11", "published_display": "10 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics CSO Lorrain Daniel S. sells $16,640 in stock By Investing.com", "summary": "Daniel S. Lorrain, CSO at Contineum Therapeutics (NASDAQ:CTNM), sold $16,640 worth of Class A Common Stock after exercising stock options. These transactions, executed under a 10b5-1 trading plan, occurred as CTNM stock approached its 52-week high, with a 283% return over the pas", "url": "https://m.in.investing.com/news/stock-market-news/contineum-therapeutics-cso-lorrain-daniel-s-sells-16640-in-stock-93CH-5492064?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-07-10T21:40:11", "published_display": "10 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choice", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNSVFZT3hwSjU5MU4teWx6YU1ycVNCeTVKWm1ydU1PcFdkMklPRXQ0ZVZRTzQ1SlJyenZxRllaYUZPWE8xdTUzTm95N1VvUlJJWnZFTFBybjhGckQxRlNKSmhhdVVycHZ6VTA0d0h2RjZfSmlCYnBaQlByN0tRcVREMlFBeVdtU0hPWjlpVGhrNkQySGZwaGdXWHRB?oc=5", "source_name": "Market source", "published_at": "2026-07-09T16:00:04+00:00", "published_display": "09 Jul 2026 16:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Contineum Therapeutics Inc For: 8 July By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNeXo3WW9KN1RqUHJMMG1lNm5oQ3FoTGFiS2h2LVhxLU1sX1NhM0ppN2kweHZsaHdHT1dZMk9fNE5FSFE3Zkh4eUgzYVAwak1ianN4QnpkUVdKdDhiM2d2dzZncnBKVFk2WTVoeTNNQTJMQmswT0YyMjVjaUotVHZWTGx4X3F3a1huZmdYMzNYUm1mR3Y3Z2xETWkwek4xUVp2ZFBHWUxtN04?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-07-08T23:03:36+00:00", "published_display": "08 Jul 2026 23:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum (CTNM) CEO sells 2,500 shares under Rule 10b5-1 plan", "summary": "Contineum Therapeutics CEO Carmine N. Stengone exercised stock options for 2,500 shares at $1.01 per share and subsequently sold those 2,500 shares at $16.00 per share on July 8, 2026. These transactions, valued at $40,000 for the sale, were conducted under a pre-arranged Rule 10", "url": "https://www.stocktitan.net/sec-filings/CTNM/form-4-contineum-therapeutics-inc-insider-trading-activity-202c31a75f79.html", "source_name": "Stock Titan", "published_at": "2026-07-08T22:40:39", "published_display": "08 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics CEO Stengone sells $40,000 in shares", "summary": "Carmine N. Stengone, CEO of Contineum Therapeutics, sold 2,500 shares of Class A Common Stock for $40,000, following the exercise of stock options. This transaction was executed under a pre-arranged 10b5-1 trading plan, occurring while the stock traded near its 52-week high and a", "url": "https://www.investing.com/news/insider-trading-news/contineum-therapeutics-ceo-stengone-sells-40000-in-shares-93CH-4782774", "source_name": "Investing.com", "published_at": "2026-07-08T22:40:39", "published_display": "08 Jul 2026 22:40", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics CSO Daniel Lorrain sells $594,578 in stock By Investing.com", "summary": "Contineum Therapeutics' Chief Scientific Officer, Daniel Lorrain, sold approximately $594,578 worth of company stock through multiple transactions on June 30 and July 1, 2026. These sales were conducted under a pre-arranged 10b5-1 trading plan and involved exercising stock option", "url": "https://za.investing.com/news/stock-market-news/contineum-therapeutics-cso-daniel-lorrain-sells-594578-in-stock-93CH-4354839", "source_name": "Investing.com South Africa", "published_at": "2026-07-03T11:40:24", "published_display": "03 Jul 2026 11:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Contineum Therapeutics Inc For: 2 July By Investing.com", "summary": "This article reports on a Form 4 filing for Contineum Therapeutics Inc. on July 2nd. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the ownership of company stock by company insiders. The article indica", "url": "https://ca.investing.com/news/stock-market-news/form-4-contineum-therapeutics-inc-for-2-july-93CH-4719262", "source_name": "Investing.com Canada", "published_at": "2026-07-03T11:13:31", "published_display": "03 Jul 2026 11:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum (NASDAQ: CTNM) CSO sells 37,179 shares and exercises 33,009 options", "summary": "Contineum Therapeutics' Chief Scientific Officer, Daniel S. Lorrain, recently sold 37,179 shares of Class A Common Stock and exercised options for 33,009 shares. These transactions, conducted under a pre-arranged Rule 10b5-1 trading plan, took place on June 30 and July 1, 2026. A", "url": "https://www.stocktitan.net/sec-filings/CTNM/form-4-contineum-therapeutics-inc-insider-trading-activity-d2c84f44e60e.html", "source_name": "Stock Titan", "published_at": "2026-07-02T22:10:00", "published_display": "02 Jul 2026 22:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics CMO Tim Watkins sells $173,590 in company stock By Investing.com", "summary": "Contineum Therapeutics' Chief Medical Officer, Tim Watkins, sold 10,833 shares of company stock for $173,590 after exercising stock options under a pre-arranged trading plan. This transaction occurred amidst a significant surge in the stock's value, which has gained almost 300% i", "url": "https://ng.investing.com/news/stock-market-news/contineum-therapeutics-cmo-tim-watkins-sells-173590-in-company-stock-93CH-2583500", "source_name": "Investing.com Nigeria", "published_at": "2026-07-02T00:18:00", "published_display": "02 Jul 2026 00:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics CEO Stengone sells $160,080 in stock", "summary": "Contineum Therapeutics CEO Carmine N. Stengone sold 10,000 shares of company stock for $160,080 and acquired 10,000 shares through option exercises for $10,725, both under a pre-arranged trading plan. These transactions occurred on June 30, 2026, with the sale happening near the ", "url": "https://www.investing.com/news/insider-trading-news/contineum-therapeutics-ceo-stengone-sells-160080-in-stock-93CH-4772025", "source_name": "Investing.com", "published_at": "2026-07-02T00:08:54", "published_display": "02 Jul 2026 00:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Contineum Therapeutics Inc For: 1 July By Investing.com", "summary": "This article reports on a Form 4 filing for Contineum Therapeutics Inc (CTNM) for activity on July 1st. Form 4 filings are used to disclose changes in beneficial ownership of securities by company insiders. The article provides the title and source, indicating it's a routine fina", "url": "https://ng.investing.com/news/stock-market-news/form-4-contineum-therapeutics-inc-for-1-july-93CH-2583490", "source_name": "Investing.com Nigeria", "published_at": "2026-07-01T23:10:01", "published_display": "01 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Contineum Therapeutics, Inc. Insider Trading Activity", "summary": "Contineum Therapeutics CEO Carmine N. Stengone exercised stock options for 10,000 shares of Class A Common Stock and subsequently sold them in an open-market transaction at a weighted average price of $16.008 per share. These transactions were executed under a pre-arranged Rule 1", "url": "https://www.stocktitan.net/sec-filings/CTNM/form-4-contineum-therapeutics-inc-insider-trading-activity-3cb3fa86111d.html", "source_name": "Stock Titan", "published_at": "2026-07-01T23:08:54", "published_display": "01 Jul 2026 23:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum (NASDAQ: CTNM) CMO sells 10,833 shares after option exercise", "summary": "Contineum Therapeutics, Inc.'s CMO & Head of Development, Tim Watkins, exercised stock options for 10,833 shares at $4.50 per share and subsequently sold them at a weighted average price of $16.0242 per share on June 30, 2026. This transaction was conducted under a Rule 10b5-1 tr", "url": "https://www.stocktitan.net/sec-filings/CTNM/form-4-contineum-therapeutics-inc-insider-trading-activity-0cf54890ab31.html", "source_name": "Stock Titan", "published_at": "2026-07-01T23:08:54", "published_display": "01 Jul 2026 23:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics CMO Tim Watkins sells $173,590 in company stock", "summary": "Contineum Therapeutics' Chief Medical Officer, Tim Watkins, sold 10,833 shares of company stock for $173,590 after acquiring them through stock option exercises. These transactions were executed under a pre-arranged trading plan, coinciding with a significant surge in the stock's", "url": "https://www.investing.com/news/insider-trading-news/contineum-therapeutics-cmo-tim-watkins-sells-173590-in-company-stock-93CH-4772042", "source_name": "Investing.com", "published_at": "2026-07-01T19:16:00", "published_display": "01 Jul 2026 19:16", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Contineum Therapeutics, Inc. SEC Filing", "summary": "This SEC Form 144 filing by Contineum Therapeutics, Inc. details a proposed sale of 10,000 shares of common stock with an aggregate market value of $150,000. The shares were acquired on June 30, 2026, through the exercise of stock options and are intended to be sold through Morga", "url": "https://www.stocktitan.net/sec-filings/CTNM/144-contineum-therapeutics-inc-sec-filing-b69748376277.html", "source_name": "Stock Titan", "published_at": "2026-07-01T12:42:05", "published_display": "01 Jul 2026 12:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider sales and option exercise at CTNM (NASDAQ: CTNM)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOS3VIX1JVd2FRazFBUW50aWUtLUM4ekExSy01U0VwYVR4VFM2eWttbDF2YVljeVQwd3Fia0RHRmpfLUMxWlVldkE5YXQ4NWFCU2ZmMmtZUVEzbFE5WjZPT0F6YmV0LWJsbUdELWNCaXhnSGZqTzN2bzdtbUx6UVVKVUhlY04yU1hWbF9NaWlabVFidDhDd0lIRG8xR3BHUlFvWmRkdWZ3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry", "summary": "Contineum Therapeutics announced the publication of a manuscript in the Journal of Medicinal Chemistry detailing the discovery and characterization of PIPE-791, a potent and brain-penetrant LPAR1 antagonist. This compound is currently in a global Phase 2 clinical trial for idiopa", "url": "https://www.biospace.com/press-releases/contineum-therapeutics-publishes-discovery-of-potential-best-in-class-lpar1-antagonist-pipe-791-in-journal-of-medicinal-chemistry", "source_name": "BioSpace", "published_at": "2026-07-01T03:39:24", "published_display": "01 Jul 2026 03:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics (CTNM) grants director 19,000 stock options at $14.19", "summary": "Contineum Therapeutics director Evert B. Schimmelpennink was granted stock options for 19,000 shares of Class A Common Stock at an exercise price of $14.19 per share under the company's 2024 Equity Incentive Plan. This is a compensation-related award, not an open-market purchase.", "url": "https://www.stocktitan.net/sec-filings/CTNM/form-4-contineum-therapeutics-inc-insider-trading-activity-bd07bf8b3614.html", "source_name": "Stock Titan", "published_at": "2026-07-01T03:07:37", "published_display": "01 Jul 2026 03:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics CEO Stengone sells $160,080 in stock By Investing.com", "summary": "Carmine N. Stengone, CEO of Contineum Therapeutics (NASDAQ:CTNM), recently sold 10,000 shares of company stock for $160,080, with the transaction occurring through a pre-arranged 10b5-1 trading plan. On the same day, he acquired 10,000 shares by exercising stock options at a lowe", "url": "https://m.au.investing.com/news/stock-market-news/contineum-therapeutics-ceo-stengone-sells-160080-in-stock-93CH-4514868?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-07-01T02:10:01", "published_display": "01 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum\u2019s PIPE-791 paper says Phase 2 drug may target fibrosis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOUktlMFR3Rl9zUGVLdnNQbktRTWMwSVRjLTJSWnpLZkwwenlnLTI5aEdjajBndHktWDRrcHF6d29EdzBhWklJNXcxeUdDLWNQazRBTlpsc1lYMjd2bHI4emlPRHYtczM5VEp6UGxMV0RrdTdPY2hPMG1iZjBLaGZZcW5sMW96cGRfRkdzanBzMkI5blI0WWk4ZlZGcjFCUS1JOEozSWtsd2RjVFpvOEVIMWswT1U3NnlBNUE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CTNM (NASDAQ) notice to sell 28,826 shares; broker Morgan Stanley named", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQbEpXS0huQ0FkbWdiUDdwVG41VmJtVC13WlVHQVVmR3JxOTNLS1lDQ0g1eFpkRXNtcmotSzVZeGZvaUxwZXdleGJyblhHRHV3WUUyZ0kxQjZhZTRXcmZzYUw3dVBCSG1IaktrbEJZREU0WUkzVGx5VGI2SWdVYzFfeDF4TVVmRGdXSGI4Q1VUX0JZakVpa2ZubjRkcExhQTc0bUFfRVZ3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum (CTNM) awards non-employee director 19,000 stock options", "summary": "Contineum Therapeutics (CTNM) has granted 19,000 stock options to non-employee director Diego Miralles as part of its standard board compensation program. The options, with an exercise price of $14.19 per share, were awarded under the company's 2024 Equity Incentive Plan and vest", "url": "https://www.stocktitan.net/sec-filings/CTNM/form-4-contineum-therapeutics-inc-insider-trading-activity-08c9740f612c.html", "source_name": "Stock Titan", "published_at": "2026-06-26T22:10:10", "published_display": "26 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics (CTNM) awards director 19,000-share stock option grant", "summary": "Contineum Therapeutics (CTNM) director Olivia C. Ware received a grant of stock options for 19,000 shares of Class A common stock, with an exercise price of $14.19 per share. These options were issued under the 2024 Equity Incentive Plan as part of the non-employee director compe", "url": "https://www.stocktitan.net/sec-filings/CTNM/form-4-contineum-therapeutics-inc-insider-trading-activity-c6622665414f.html", "source_name": "Stock Titan", "published_at": "2026-06-26T21:39:25", "published_display": "26 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics (CTNM) director receives 19,000 stock options grant", "summary": "Contineum Therapeutics director Lori Lyons-Williams was granted 19,000 stock options under the company\u2019s 2024 Equity Incentive Plan. These options, tied to Class A Common Stock, have an exercise price of $14.19 per share and expire on June 25, 2036. The grant is part of the Non-E", "url": "https://www.stocktitan.net/sec-filings/CTNM/form-4-contineum-therapeutics-inc-insider-trading-activity-4722f0843062.html", "source_name": "Stock Titan", "published_at": "2026-06-26T21:39:25", "published_display": "26 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics (CTNM) elects Class II directors, ratifies Ernst & Young as 2026 auditor", "summary": "Contineum Therapeutics, Inc. (CTNM) held its 2026 Annual Meeting of Stockholders on June 26, 2026. During the meeting, stockholders elected three Class II directors\u2014Evert Schimmelpennink, Lori M. Lyons-Williams, and Diego Miralles, M.D.\u2014to serve until the 2029 annual meeting. Add", "url": "https://www.stocktitan.net/sec-filings/CTNM/8-k-contineum-therapeutics-inc-reports-material-event-519777822e0b.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:39:25", "published_display": "26 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Stockholders Hold 2026 Virtual Annual Meeting", "summary": "Contineum Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders virtually on June 26, 2026. Stockholders re-elected three Class II directors and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026. Anal", "url": "https://www.theglobeandmail.com/investing/markets/stocks/CTNM-Q/pressreleases/3017561/contineum-stockholders-hold-2026-virtual-annual-meeting/", "source_name": "The Globe and Mail", "published_at": "2026-06-26T13:39:32", "published_display": "26 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics, Inc. Class A Actuals & Estimates (NASDAQ:CTNM)", "summary": "This article provides an overview of Contineum Therapeutics, Inc. (NASDAQ: CTNM) stock, including its current price, market capitalization, historical performance, and analyst forecasts. It also details financial estimates like earnings per share and revenue, and notes that the c", "url": "https://www.tradingview.com/symbols/NASDAQ-CTNM/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T08:10:52", "published_display": "26 Jun 2026 08:10", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics (NASDAQ: CTNM) grants director 19,000 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNRTA3enZvSUpDNWx2SjdmODVlS25OdjFpQVpobWpvQlVrSGhVc2t0VWVxNnFhNHh4dWd4NU1DUDZGVzI2X0RpMmo1MnIydjJZVUV0Z2R3N2JaUXoxT1FlWnhpc3NqSDA1WXQ3NWFoSTFubFJOWjZYb05VMFFjV1ZUbkxLNkhnRDI4QTVDM1IxSFVoeWRWc2U4Qk15Y1VkUGM4c1RfX003NzNwX0ZYLTh5a3NUYndrSFF2Uk9veQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/contineum-therapeutics-present-2026-goldman-200500880.html", "source_name": "Business Wire", "published_at": "2026-06-01T20:05:00+00:00", "published_display": "01 Jun 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts See a 59.96% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wall-street-analysts-see-59-135502167.html", "source_name": "Zacks", "published_at": "2026-05-25T13:55:02+00:00", "published_display": "25 May 2026 13:55", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential", "summary": "", "url": "https://finance.yahoo.com/m/0e99d37a-3821-3a87-9c23-392700d22f24/contineum-therapeutics-touts.html", "source_name": "MarketBeat", "published_at": "2026-05-22T12:03:58+00:00", "published_display": "22 May 2026 12:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Morgan Stanley Raises Price Target on Contineum Therapeutics to $16 From $14, Keeps Equalweight Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/morgan-stanley-raises-price-target-105053653.html", "source_name": "MT Newswires", "published_at": "2026-05-14T10:50:53+00:00", "published_display": "14 May 2026 10:50", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 49.21%: Read This Before Placing a Bet", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wall-street-analysts-think-contineum-135504987.html", "source_name": "Zacks", "published_at": "2026-05-08T13:55:04+00:00", "published_display": "08 May 2026 13:55", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CTNM (NASDAQ: CTNM) affiliate reports multiple 10b5-1 sales by Daniel Lorrain", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTF9lbnNMRkR0Qm1md3JFNDFGZ0dpWkg1YmROelhQZFlybG9rczdhOWF6MG9sYUZNeDdNclA1bFFpWnNGLVNiSlFpbTMyVHpkWktxQlNvdzZCZ2JMS0Jnd0pzbkpRZjFZaHdENTdoRVp2SUpoN0Fuek9mdlR4WWFDdlpKVGR2NlM0dDhJakRMU2Q4d3dXV05wMllMZDNuR291Y0U4aVd3?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "We Think Contineum Therapeutics (NASDAQ:CTNM) Can Afford To Drive Business Growth", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/think-contineum-therapeutics-nasdaq-ctnm-120352132.html", "source_name": "Simply Wall St.", "published_at": "2026-04-19T12:03:52+00:00", "published_display": "19 Apr 2026 12:03", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics Announces Proposed $75.0 Million Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPSzlKX0xZMEhUTVNyWG5leWdxN2FTbFh5aS0yVkJLRlgtUmZsanJjRllWM0p4Nno2Z3FzRUZDcWZSaW1XRzZycFlDcEVhcDNCUmtfck1ZMmU1WUtzWVA5MHhWUlJPUld0YW0zbXR6NWtjQjBDTkxwSk5IY0tDNGNlT3RuZkZjRUVlNmNVTkJYZ1NJTXpJdjBLMXlyeC1rbkJ4ZWJXcThjeC1GOUo1RnZSd0xqcEg0SUwxczlISG5mTDdFa2pPQjVkNXpR?oc=5", "source_name": "Business Wire", "published_at": "2025-12-11T08:00:00+00:00", "published_display": "11 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics (CTNM) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1salBsRW9ONmVPaHlCQW1sYVlYMkpLOU5STW1fd2R0M1pMbVR4TFM4Y0hxSmQ3WmZnSkpPTzZPRWREQkpVZUEyaklzUkFDSU9maDVuNFE2LVdTUQ?oc=5", "source_name": "MarketBeat", "published_at": "2024-04-06T01:26:16+00:00", "published_display": "06 Apr 2024 01:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Contineum Therapeutics CSO Lorrain Daniel S. sells $16,640 in stock", "summary": "Contineum Therapeutics' Chief Scientific Officer, Daniel S. Lorrain, sold 1,040 shares of the company's Class A Common Stock for a total of $16,640 on July 8 and 9, 2026. These sales followed an exercise of stock options at a price of $1.01 per share and were conducted under a 10", "url": "https://www.investing.com/news/insider-trading-news/contineum-therapeutics-cso-lorrain-daniel-s-sells-16640-in-stock-93CH-4787023", "source_name": "Investing.com", "published_at": "2026-07-11T14:41:12", "published_display": "11 Jul 2026 14:41", "sentiment": "negative", "sentiment_pct": 41, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics (NASDAQ: CTNM) CSO sells 1,040 shares, exercises options", "summary": "Contineum Therapeutics' Chief Scientific Officer, Daniel S. Lorrain, exercised options for 1,040 shares at $1.01 each and subsequently sold those shares at $16.00 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted in September 202", "url": "https://www.stocktitan.net/sec-filings/CTNM/form-4-contineum-therapeutics-inc-insider-trading-activity-58d2336ab72b.html", "source_name": "Stock Titan", "published_at": "2026-07-10T21:40:11", "published_display": "10 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics CSO Lorrain Daniel S. sells $16,640 in stock By Investing.com", "summary": "Daniel S. Lorrain, CSO at Contineum Therapeutics (NASDAQ:CTNM), sold $16,640 worth of Class A Common Stock after exercising stock options. These transactions, executed under a 10b5-1 trading plan, occurred as CTNM stock approached its 52-week high, with a 283% return over the pas", "url": "https://m.in.investing.com/news/stock-market-news/contineum-therapeutics-cso-lorrain-daniel-s-sells-16640-in-stock-93CH-5492064?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-07-10T21:40:11", "published_display": "10 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choice", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxNSVFZT3hwSjU5MU4teWx6YU1ycVNCeTVKWm1ydU1PcFdkMklPRXQ0ZVZRTzQ1SlJyenZxRllaYUZPWE8xdTUzTm95N1VvUlJJWnZFTFBybjhGckQxRlNKSmhhdVVycHZ6VTA0d0h2RjZfSmlCYnBaQlByN0tRcVREMlFBeVdtU0hPWjlpVGhrNkQySGZwaGdXWHRB?oc=5", "source_name": "Market source", "published_at": "2026-07-09T16:00:04+00:00", "published_display": "09 Jul 2026 16:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Contineum Therapeutics Inc For: 8 July By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNeXo3WW9KN1RqUHJMMG1lNm5oQ3FoTGFiS2h2LVhxLU1sX1NhM0ppN2kweHZsaHdHT1dZMk9fNE5FSFE3Zkh4eUgzYVAwak1ianN4QnpkUVdKdDhiM2d2dzZncnBKVFk2WTVoeTNNQTJMQmswT0YyMjVjaUotVHZWTGx4X3F3a1huZmdYMzNYUm1mR3Y3Z2xETWkwek4xUVp2ZFBHWUxtN04?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-07-08T23:03:36+00:00", "published_display": "08 Jul 2026 23:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum (CTNM) CEO sells 2,500 shares under Rule 10b5-1 plan", "summary": "Contineum Therapeutics CEO Carmine N. Stengone exercised stock options for 2,500 shares at $1.01 per share and subsequently sold those 2,500 shares at $16.00 per share on July 8, 2026. These transactions, valued at $40,000 for the sale, were conducted under a pre-arranged Rule 10", "url": "https://www.stocktitan.net/sec-filings/CTNM/form-4-contineum-therapeutics-inc-insider-trading-activity-202c31a75f79.html", "source_name": "Stock Titan", "published_at": "2026-07-08T22:40:39", "published_display": "08 Jul 2026 22:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics CEO Stengone sells $40,000 in shares", "summary": "Carmine N. Stengone, CEO of Contineum Therapeutics, sold 2,500 shares of Class A Common Stock for $40,000, following the exercise of stock options. This transaction was executed under a pre-arranged 10b5-1 trading plan, occurring while the stock traded near its 52-week high and a", "url": "https://www.investing.com/news/insider-trading-news/contineum-therapeutics-ceo-stengone-sells-40000-in-shares-93CH-4782774", "source_name": "Investing.com", "published_at": "2026-07-08T22:40:39", "published_display": "08 Jul 2026 22:40", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics CSO Daniel Lorrain sells $594,578 in stock By Investing.com", "summary": "Contineum Therapeutics' Chief Scientific Officer, Daniel Lorrain, sold approximately $594,578 worth of company stock through multiple transactions on June 30 and July 1, 2026. These sales were conducted under a pre-arranged 10b5-1 trading plan and involved exercising stock option", "url": "https://za.investing.com/news/stock-market-news/contineum-therapeutics-cso-daniel-lorrain-sells-594578-in-stock-93CH-4354839", "source_name": "Investing.com South Africa", "published_at": "2026-07-03T11:40:24", "published_display": "03 Jul 2026 11:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Contineum Therapeutics Inc For: 2 July By Investing.com", "summary": "This article reports on a Form 4 filing for Contineum Therapeutics Inc. on July 2nd. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the ownership of company stock by company insiders. The article indica", "url": "https://ca.investing.com/news/stock-market-news/form-4-contineum-therapeutics-inc-for-2-july-93CH-4719262", "source_name": "Investing.com Canada", "published_at": "2026-07-03T11:13:31", "published_display": "03 Jul 2026 11:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum (NASDAQ: CTNM) CSO sells 37,179 shares and exercises 33,009 options", "summary": "Contineum Therapeutics' Chief Scientific Officer, Daniel S. Lorrain, recently sold 37,179 shares of Class A Common Stock and exercised options for 33,009 shares. These transactions, conducted under a pre-arranged Rule 10b5-1 trading plan, took place on June 30 and July 1, 2026. A", "url": "https://www.stocktitan.net/sec-filings/CTNM/form-4-contineum-therapeutics-inc-insider-trading-activity-d2c84f44e60e.html", "source_name": "Stock Titan", "published_at": "2026-07-02T22:10:00", "published_display": "02 Jul 2026 22:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics CMO Tim Watkins sells $173,590 in company stock By Investing.com", "summary": "Contineum Therapeutics' Chief Medical Officer, Tim Watkins, sold 10,833 shares of company stock for $173,590 after exercising stock options under a pre-arranged trading plan. This transaction occurred amidst a significant surge in the stock's value, which has gained almost 300% i", "url": "https://ng.investing.com/news/stock-market-news/contineum-therapeutics-cmo-tim-watkins-sells-173590-in-company-stock-93CH-2583500", "source_name": "Investing.com Nigeria", "published_at": "2026-07-02T00:18:00", "published_display": "02 Jul 2026 00:18", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics CEO Stengone sells $160,080 in stock", "summary": "Contineum Therapeutics CEO Carmine N. Stengone sold 10,000 shares of company stock for $160,080 and acquired 10,000 shares through option exercises for $10,725, both under a pre-arranged trading plan. These transactions occurred on June 30, 2026, with the sale happening near the ", "url": "https://www.investing.com/news/insider-trading-news/contineum-therapeutics-ceo-stengone-sells-160080-in-stock-93CH-4772025", "source_name": "Investing.com", "published_at": "2026-07-02T00:08:54", "published_display": "02 Jul 2026 00:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Contineum Therapeutics Inc For: 1 July By Investing.com", "summary": "This article reports on a Form 4 filing for Contineum Therapeutics Inc (CTNM) for activity on July 1st. Form 4 filings are used to disclose changes in beneficial ownership of securities by company insiders. The article provides the title and source, indicating it's a routine fina", "url": "https://ng.investing.com/news/stock-market-news/form-4-contineum-therapeutics-inc-for-1-july-93CH-2583490", "source_name": "Investing.com Nigeria", "published_at": "2026-07-01T23:10:01", "published_display": "01 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] Contineum Therapeutics, Inc. Insider Trading Activity", "summary": "Contineum Therapeutics CEO Carmine N. Stengone exercised stock options for 10,000 shares of Class A Common Stock and subsequently sold them in an open-market transaction at a weighted average price of $16.008 per share. These transactions were executed under a pre-arranged Rule 1", "url": "https://www.stocktitan.net/sec-filings/CTNM/form-4-contineum-therapeutics-inc-insider-trading-activity-3cb3fa86111d.html", "source_name": "Stock Titan", "published_at": "2026-07-01T23:08:54", "published_display": "01 Jul 2026 23:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum (NASDAQ: CTNM) CMO sells 10,833 shares after option exercise", "summary": "Contineum Therapeutics, Inc.'s CMO & Head of Development, Tim Watkins, exercised stock options for 10,833 shares at $4.50 per share and subsequently sold them at a weighted average price of $16.0242 per share on June 30, 2026. This transaction was conducted under a Rule 10b5-1 tr", "url": "https://www.stocktitan.net/sec-filings/CTNM/form-4-contineum-therapeutics-inc-insider-trading-activity-0cf54890ab31.html", "source_name": "Stock Titan", "published_at": "2026-07-01T23:08:54", "published_display": "01 Jul 2026 23:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics CMO Tim Watkins sells $173,590 in company stock", "summary": "Contineum Therapeutics' Chief Medical Officer, Tim Watkins, sold 10,833 shares of company stock for $173,590 after acquiring them through stock option exercises. These transactions were executed under a pre-arranged trading plan, coinciding with a significant surge in the stock's", "url": "https://www.investing.com/news/insider-trading-news/contineum-therapeutics-cmo-tim-watkins-sells-173590-in-company-stock-93CH-4772042", "source_name": "Investing.com", "published_at": "2026-07-01T19:16:00", "published_display": "01 Jul 2026 19:16", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] Contineum Therapeutics, Inc. SEC Filing", "summary": "This SEC Form 144 filing by Contineum Therapeutics, Inc. details a proposed sale of 10,000 shares of common stock with an aggregate market value of $150,000. The shares were acquired on June 30, 2026, through the exercise of stock options and are intended to be sold through Morga", "url": "https://www.stocktitan.net/sec-filings/CTNM/144-contineum-therapeutics-inc-sec-filing-b69748376277.html", "source_name": "Stock Titan", "published_at": "2026-07-01T12:42:05", "published_display": "01 Jul 2026 12:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider sales and option exercise at CTNM (NASDAQ: CTNM)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxOS3VIX1JVd2FRazFBUW50aWUtLUM4ekExSy01U0VwYVR4VFM2eWttbDF2YVljeVQwd3Fia0RHRmpfLUMxWlVldkE5YXQ4NWFCU2ZmMmtZUVEzbFE5WjZPT0F6YmV0LWJsbUdELWNCaXhnSGZqTzN2bzdtbUx6UVVKVUhlY04yU1hWbF9NaWlabVFidDhDd0lIRG8xR3BHUlFvWmRkdWZ3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry", "summary": "Contineum Therapeutics announced the publication of a manuscript in the Journal of Medicinal Chemistry detailing the discovery and characterization of PIPE-791, a potent and brain-penetrant LPAR1 antagonist. This compound is currently in a global Phase 2 clinical trial for idiopa", "url": "https://www.biospace.com/press-releases/contineum-therapeutics-publishes-discovery-of-potential-best-in-class-lpar1-antagonist-pipe-791-in-journal-of-medicinal-chemistry", "source_name": "BioSpace", "published_at": "2026-07-01T03:39:24", "published_display": "01 Jul 2026 03:39", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics (CTNM) grants director 19,000 stock options at $14.19", "summary": "Contineum Therapeutics director Evert B. Schimmelpennink was granted stock options for 19,000 shares of Class A Common Stock at an exercise price of $14.19 per share under the company's 2024 Equity Incentive Plan. This is a compensation-related award, not an open-market purchase.", "url": "https://www.stocktitan.net/sec-filings/CTNM/form-4-contineum-therapeutics-inc-insider-trading-activity-bd07bf8b3614.html", "source_name": "Stock Titan", "published_at": "2026-07-01T03:07:37", "published_display": "01 Jul 2026 03:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics CEO Stengone sells $160,080 in stock By Investing.com", "summary": "Carmine N. Stengone, CEO of Contineum Therapeutics (NASDAQ:CTNM), recently sold 10,000 shares of company stock for $160,080, with the transaction occurring through a pre-arranged 10b5-1 trading plan. On the same day, he acquired 10,000 shares by exercising stock options at a lowe", "url": "https://m.au.investing.com/news/stock-market-news/contineum-therapeutics-ceo-stengone-sells-160080-in-stock-93CH-4514868?ampMode=1", "source_name": "Investing.com Australia", "published_at": "2026-07-01T02:10:01", "published_display": "01 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum\u2019s PIPE-791 paper says Phase 2 drug may target fibrosis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOUktlMFR3Rl9zUGVLdnNQbktRTWMwSVRjLTJSWnpLZkwwenlnLTI5aEdjajBndHktWDRrcHF6d29EdzBhWklJNXcxeUdDLWNQazRBTlpsc1lYMjd2bHI4emlPRHYtczM5VEp6UGxMV0RrdTdPY2hPMG1iZjBLaGZZcW5sMW96cGRfRkdzanBzMkI5blI0WWk4ZlZGcjFCUS1JOEozSWtsd2RjVFpvOEVIMWswT1U3NnlBNUE?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CTNM (NASDAQ) notice to sell 28,826 shares; broker Morgan Stanley named", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxQbEpXS0huQ0FkbWdiUDdwVG41VmJtVC13WlVHQVVmR3JxOTNLS1lDQ0g1eFpkRXNtcmotSzVZeGZvaUxwZXdleGJyblhHRHV3WUUyZ0kxQjZhZTRXcmZzYUw3dVBCSG1IaktrbEJZREU0WUkzVGx5VGI2SWdVYzFfeDF4TVVmRGdXSGI4Q1VUX0JZakVpa2ZubjRkcExhQTc0bUFfRVZ3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-30T07:00:00+00:00", "published_display": "30 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum (CTNM) awards non-employee director 19,000 stock options", "summary": "Contineum Therapeutics (CTNM) has granted 19,000 stock options to non-employee director Diego Miralles as part of its standard board compensation program. The options, with an exercise price of $14.19 per share, were awarded under the company's 2024 Equity Incentive Plan and vest", "url": "https://www.stocktitan.net/sec-filings/CTNM/form-4-contineum-therapeutics-inc-insider-trading-activity-08c9740f612c.html", "source_name": "Stock Titan", "published_at": "2026-06-26T22:10:10", "published_display": "26 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics (CTNM) awards director 19,000-share stock option grant", "summary": "Contineum Therapeutics (CTNM) director Olivia C. Ware received a grant of stock options for 19,000 shares of Class A common stock, with an exercise price of $14.19 per share. These options were issued under the 2024 Equity Incentive Plan as part of the non-employee director compe", "url": "https://www.stocktitan.net/sec-filings/CTNM/form-4-contineum-therapeutics-inc-insider-trading-activity-c6622665414f.html", "source_name": "Stock Titan", "published_at": "2026-06-26T21:39:25", "published_display": "26 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics (CTNM) director receives 19,000 stock options grant", "summary": "Contineum Therapeutics director Lori Lyons-Williams was granted 19,000 stock options under the company\u2019s 2024 Equity Incentive Plan. These options, tied to Class A Common Stock, have an exercise price of $14.19 per share and expire on June 25, 2036. The grant is part of the Non-E", "url": "https://www.stocktitan.net/sec-filings/CTNM/form-4-contineum-therapeutics-inc-insider-trading-activity-4722f0843062.html", "source_name": "Stock Titan", "published_at": "2026-06-26T21:39:25", "published_display": "26 Jun 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics (CTNM) elects Class II directors, ratifies Ernst & Young as 2026 auditor", "summary": "Contineum Therapeutics, Inc. (CTNM) held its 2026 Annual Meeting of Stockholders on June 26, 2026. During the meeting, stockholders elected three Class II directors\u2014Evert Schimmelpennink, Lori M. Lyons-Williams, and Diego Miralles, M.D.\u2014to serve until the 2029 annual meeting. Add", "url": "https://www.stocktitan.net/sec-filings/CTNM/8-k-contineum-therapeutics-inc-reports-material-event-519777822e0b.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:39:25", "published_display": "26 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Stockholders Hold 2026 Virtual Annual Meeting", "summary": "Contineum Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders virtually on June 26, 2026. Stockholders re-elected three Class II directors and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026. Anal", "url": "https://www.theglobeandmail.com/investing/markets/stocks/CTNM-Q/pressreleases/3017561/contineum-stockholders-hold-2026-virtual-annual-meeting/", "source_name": "The Globe and Mail", "published_at": "2026-06-26T13:39:32", "published_display": "26 Jun 2026 13:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics, Inc. Class A Actuals & Estimates (NASDAQ:CTNM)", "summary": "This article provides an overview of Contineum Therapeutics, Inc. (NASDAQ: CTNM) stock, including its current price, market capitalization, historical performance, and analyst forecasts. It also details financial estimates like earnings per share and revenue, and notes that the c", "url": "https://www.tradingview.com/symbols/NASDAQ-CTNM/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T08:10:52", "published_display": "26 Jun 2026 08:10", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics (NASDAQ: CTNM) grants director 19,000 stock options", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxNRTA3enZvSUpDNWx2SjdmODVlS25OdjFpQVpobWpvQlVrSGhVc2t0VWVxNnFhNHh4dWd4NU1DUDZGVzI2X0RpMmo1MnIydjJZVUV0Z2R3N2JaUXoxT1FlWnhpc3NqSDA1WXQ3NWFoSTFubFJOWjZYb05VMFFjV1ZUbkxLNkhnRDI4QTVDM1IxSFVoeWRWc2U4Qk15Y1VkUGM4c1RfX003NzNwX0ZYLTh5a3NUYndrSFF2Uk9veQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-26T07:00:00+00:00", "published_display": "26 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/contineum-therapeutics-present-2026-goldman-200500880.html", "source_name": "Business Wire", "published_at": "2026-06-01T20:05:00+00:00", "published_display": "01 Jun 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts See a 59.96% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High?", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wall-street-analysts-see-59-135502167.html", "source_name": "Zacks", "published_at": "2026-05-25T13:55:02+00:00", "published_display": "25 May 2026 13:55", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential", "summary": "", "url": "https://finance.yahoo.com/m/0e99d37a-3821-3a87-9c23-392700d22f24/contineum-therapeutics-touts.html", "source_name": "MarketBeat", "published_at": "2026-05-22T12:03:58+00:00", "published_display": "22 May 2026 12:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Morgan Stanley Raises Price Target on Contineum Therapeutics to $16 From $14, Keeps Equalweight Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/morgan-stanley-raises-price-target-105053653.html", "source_name": "MT Newswires", "published_at": "2026-05-14T10:50:53+00:00", "published_display": "14 May 2026 10:50", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 49.21%: Read This Before Placing a Bet", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wall-street-analysts-think-contineum-135504987.html", "source_name": "Zacks", "published_at": "2026-05-08T13:55:04+00:00", "published_display": "08 May 2026 13:55", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CTNM (NASDAQ: CTNM) affiliate reports multiple 10b5-1 sales by Daniel Lorrain", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNTF9lbnNMRkR0Qm1md3JFNDFGZ0dpWkg1YmROelhQZFlybG9rczdhOWF6MG9sYUZNeDdNclA1bFFpWnNGLVNiSlFpbTMyVHpkWktxQlNvdzZCZ2JMS0Jnd0pzbkpRZjFZaHdENTdoRVp2SUpoN0Fuek9mdlR4WWFDdlpKVGR2NlM0dDhJakRMU2Q4d3dXV05wMllMZDNuR291Y0U4aVd3?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Think Contineum Therapeutics (NASDAQ:CTNM) Can Afford To Drive Business Growth", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/think-contineum-therapeutics-nasdaq-ctnm-120352132.html", "source_name": "Simply Wall St.", "published_at": "2026-04-19T12:03:52+00:00", "published_display": "19 Apr 2026 12:03", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Vir Biotechnology Stock Skyrockets 65% on Positive Prostate Cancer Treatment Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNeEtXZ1k1WGctLWZuX0tYZE5SLWN4MU5KUktLV3NobzVheFpoMkZhdFJrWTdNelAwWGxYZUswazZtMWFUaXEzY3k0QnI0TW9IMGc2UTNzUlNmR1JxZG1JbEpQM0N3N1p4blRjaGdvMExoZzJOYWF3Tk5hajJCTlprZ3dESTVEd0Y4TXhvcElNR3Bqemd3RmNKcGxwa2dSU2phak9paE53c0t3dVFVeGZic2liZ1I0UU80TEM2WUNlOA?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "This Small-Cap Biotech Stock Is Soaring 29% on Excitement Over Its Prostate Cancer Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxPSG1pQzVIRmhqTkhiWXozT29mTWM0UERfakxmOTZzdm5TZ24wZTVqLUpSWlFyWGVmYnlicGE3ZVYxOVotWU5naGM5aUZVakItUGJLTk1ZVE1mclRHd1N3N0FIWkV2TzFrT2lMNFRjcHhnVVBzTk5vNUFkLTgwNExtRWJYN1hVZzRkVjRlTktkNk1jcnpfQklCamN3NA?oc=5", "source_name": "Barron's", "published_at": "2026-02-24T08:00:00+00:00", "published_display": "24 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics Announces Proposed $75.0 Million Public Offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPSzlKX0xZMEhUTVNyWG5leWdxN2FTbFh5aS0yVkJLRlgtUmZsanJjRllWM0p4Nno2Z3FzRUZDcWZSaW1XRzZycFlDcEVhcDNCUmtfck1ZMmU1WUtzWVA5MHhWUlJPUld0YW0zbXR6NWtjQjBDTkxwSk5IY0tDNGNlT3RuZkZjRUVlNmNVTkJYZ1NJTXpJdjBLMXlyeC1rbkJ4ZWJXcThjeC1GOUo1RnZSd0xqcEg0SUwxczlISG5mTDdFa2pPQjVkNXpR?oc=5", "source_name": "Business Wire", "published_at": "2025-12-11T08:00:00+00:00", "published_display": "11 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contineum Therapeutics (CTNM) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1salBsRW9ONmVPaHlCQW1sYVlYMkpLOU5STW1fd2R0M1pMbVR4TFM4Y0hxSmQ3WmZnSkpPTzZPRWREQkpVZUEyaklzUkFDSU9maDVuNFE2LVdTUQ?oc=5", "source_name": "MarketBeat", "published_at": "2024-04-06T01:26:16+00:00", "published_display": "06 Apr 2024 01:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 85, "total_relevant": 57, "sentiment_summary": {"positive": 10, "negative": 8, "neutral": 39, "score": 51, "total": 57, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 86, "events": [{"event": "general", "label": "Market update", "weight": 23.6, "count": 41}, {"event": "earnings", "label": "Earnings", "weight": 7.09, "count": 14}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}], "positive_events": 10, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 15.19, "latest_week": "2026-07-10", "one_week_move": 0.6, "four_week_move": 27.9, "twelve_week_move": 12.3, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.021638, "market_dynamics_buy_signal": false, "relative_strength": 9.964709, "fair_value_gap": 23.6, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 50.3356, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+0.6% over one week, +27.9% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 51, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 16}, {"label": "Market source", "count": 7}, {"label": "Investing.com", "count": 4}, {"label": "TradingView", "count": 3}, {"label": "Investing.com Canada", "count": 2}, {"label": "Investing.com Nigeria", "count": 2}, {"label": "Business Wire", "count": 2}, {"label": "Zacks", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 50}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 41}, {"label": "Earnings", "count": 14}, {"label": "Analyst action", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "86/100 classification confidence."}, {"label": "Company focus", "value": "50", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "4", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+0.6% over one week, +27.9% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Contineum Therapeutics CSO Lorrain Daniel S. sells $16,640 in stock"}], "updated_at": "2026-07-16T02:16:18.830671+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}